Evaluation of a pre-exposure prophylaxis programme for men who have sex with men and transgender women in Thailand: learning through the HIV prevention cascade lens

Reshmie A Ramautarsing, Ratchadaporn Meksena, Thanthip Sungsing, Tanat Chinbunchorn, Theeranat Sangprasert, Orawan Fungfoosri, Dusita Meekrua, Saman Sumalu, Thapana Pasansai, Witwasin Bunainso, Tashada Wongsri, Nuttakrit Mainoy, Donn Colby, Matthew Avery, Stephen Mills, Ravipa Vannakit, Praphan Phanuphak, Nittaya Phanuphak, Reshmie A Ramautarsing, Ratchadaporn Meksena, Thanthip Sungsing, Tanat Chinbunchorn, Theeranat Sangprasert, Orawan Fungfoosri, Dusita Meekrua, Saman Sumalu, Thapana Pasansai, Witwasin Bunainso, Tashada Wongsri, Nuttakrit Mainoy, Donn Colby, Matthew Avery, Stephen Mills, Ravipa Vannakit, Praphan Phanuphak, Nittaya Phanuphak

Abstract

Introduction: Men who have sex with men (MSM) and transgender women (TGW) are two key populations (KPs) in Thailand at high risk for HIV. Uptake and scale-up of pre-exposure prophylaxis (PrEP) among them has been slow. We used data from Princess PrEP, Thailand's largest KP-led PrEP programme, to operationalize PrEP service cascades. We identified gaps and pointed out where additional data are needed to inform a larger HIV prevention cascade.

Methods: Numbers of people tested for HIV, tested HIV negative, eligible for PrEP (defined as any of the following in the past three months: condomless sex with partners of unknown/uncertain HIV status or antiretroviral treatment or viral load status, multiple partners, engaging in sex work, sexually transmitted infections, injecting drugs, using amphetamine-type stimulants, or repeated use of post-exposure prophylaxis), offered PrEP and accepted PrEP during January to November 2019 were retrieved from Princess PrEP database to inform PrEP service cascades for MSM and TGW. Reasons for not accepting PrEP were documented.

Results: Of 6287 MSM who received HIV testing in Princess PrEP, 92.3% were HIV negative and 70.2% of them were eligible for PrEP. PrEP was offered to 94.7% of those eligible and 48.0% of those offered accepted it. Among 900 TGW who had HIV testing, 95.3% tested HIV negative and 64.8% of them met PrEP eligibility criteria. Of these, 95.0% were offered PrEP and 43.9% of them accepted it. Among MSM and TGW who met PrEP eligibility criteria, no or low-HIV-risk perception was the most common reason provided (46.7% of 2007 MSM and 41.9% of 296 TGW) for not accepting PrEP.

Conclusions: PrEP service cascades from the Princess PrEP programme identified no or low-risk perception as key barrier to PrEP acceptance among MSM and TGW who met PrEP eligibility criteria. More implementation research studies are needed to explore PrEP motivation and access in larger communities outside of clinical services. This is to identify gaps and strategies to address them within motivation, access and effective use domains of the HIV prevention cascade.

Keywords: HIV prevention; Thailand; men who have sex with men; pre-exposure prophylaxis; prevention cascade; transgender women.

© 2020 The Authors. Journal of the International AIDS Society published by John Wiley & Sons Ltd on behalf of the International AIDS Society.

Figures

Figure 1
Figure 1
PrEP service cascade for men who have sex with men in the Princess PrEP programme, overall and by age group. PrEP eligibility criteria: Any of the following in the previous three months: condomless sex with unknown HIV status partner(s), condomless sex with HIV‐positive partner(s) not on antiretroviral treatment (ART) or on ART with uncertain viral load status or unknown ART status, having multiple partners, engaging in sex work, symptoms or diagnosis of STIs, injecting drugs, using amphetamine‐type stimulants (ATS), or repeated use of post‐exposure prophylaxis (PEP). PrEP, pre‐exposure prophylaxis; MSM, men who have sex with men; M1, month 1 visit; M3, month 3 visit.
Figure 2
Figure 2
PrEP service cascade for transgender women in Princess PrEP programme, overall and by age group. PrEP eligibility criteria: Any of the following in the previous three months: condomless sex with unknown HIV status partner(s), condomless sex with HIV‐positive partner(s) not on antiretroviral treatment (ART) or on ART with uncertain viral load status or unknown ART status, having multiple partners, engaging in sex work, symptoms or diagnosis of STIs, injecting drugs, using amphetamine‐type stimulants (ATS), or repeated use of post‐exposure prophylaxis (PEP). PrEP, pre‐exposure prophylaxis; TGW, transgender women; M1, month 1 visit; M3, month 3 visit.

References

    1. Nwokolo N, Hill A, McOwan A, Pozniak A. Rapidly declining HIV infection in MSM in central London. Lancet HIV. 2017;4(11):e482–3.
    1. Grulich AE, Guy R, Amin J, Jin F, Selvey C, Holden J, et al. Population‐level effectiveness of rapid, targeted, high‐coverage roll‐out of HIV pre‐exposure prophylaxis in men who have sex with men: the EPIC‐NSW prospective cohort study. Lancet HIV. 2018;5(11):e629–37.
    1. Schaefer R, Gregson S, Fearon E, Hensen B, Hallett TB, Hargreaves JR. HIV prevention cascades: a unifying framework to replicate the successes of treatment cascades. Lancet HIV. 2019;6(1):e60–6.
    1. Thailand Working Group on HIV/AIDS Projection . AIDS Epidemic Model Projection for HIV/AIDS in Thailand 2010‐2030. Summary Report. 2010.
    1. Joint United Nations . Program on HIV/AIDS (UNAIDS). Prevention GapReport. 2016.
    1. Seekaew P, Pengnonyang S, Jantarapakde J, Sungsing T, Rodbumrung P, Trachunthong D, et al. Characteristics and HIV epidemiologic profiles of men who have sex with men and transgender women in key population‐led test and treat cohorts in Thailand. PLoS One. 2018;13:e0203294.
    1. Funding boost for healthcare: The Nation; 2019. [cited 2020 May 31]. Available from:
    1. NHSO board adds PrEP for high risk populations to fiscal year 2020 budget (Thai language). National Health Security Office; 2019. [cited 2020 May 31]. Available from: ;
    1. Phanuphak N, Sungsing T, Jantarapakde J, Pengnonyang S, Trachunthong D, Mingkwanrungruang P, et al. Princess PrEP program: the first key population‐led model to deliver pre‐exposure prophylaxis to key populations by key populations in Thailand. Sex Health. 2018;15(6):542–55.
    1. Thai Red Cross AIDS Research Centre and FHI 360 . Differentiated HIV Service Delivery along the cascade for men who have sex with men and transgender women in Thailand: lessons learned from the LINKGAGES project [cited 2020 May 31]. Available from: .
    1. Phanuphak N, Jantarapakde J, Himmad L, Sungsing T, Meksena R, Phomthong S, et al. Linkages to HIV confirmatory testing and antiretroviral therapy after online, supervised, HIV self‐testing among Thai men who have sex with men and transgender women. J Int AIDS Soc. 2020;23:e25448.
    1. Thailand National AIDS Committee . Thailand National Operational Plan Accelerating Ending AIDS 2015‐2019. 2014.
    1. International AIDS Society . IAS statement on U=U: Putting the science into action [cited 2020 May 31]. Available from:
    1. Hiransuthikul A, Janamnuaysook R, Himmad K, et al. Drug‐drug interactions between feminizing hormone therapy and pre‐exposure prophylaxis among transgender women: the iFACT study. J Int AIDS Soc. 2019;22(7):e25338.
    1. Cottrell ML, Prince HMA, Schauer AP, Sykes C, Maffuid K, Poliseno A, et al. Decreased tenofovir diphosphate concentrations in a transgender female cohort: Implications for HIV pre‐exposure prophylaxis (PrEP). Clin Infect Dis. 2019;69(12):2201‐4.
    1. Department of Disease Control, Thailand Ministry of Public Health . Thailand National Guidelines on Pre‐Exposure Prophylaxis: HIV‐PrEP. 2018. [cited 2020 April 19]. Available from:
    1. Hull SJ. Perceived risk as a moderator of the effectiveness of framed HIV‐test promotion messages among women: a randomized controlled trial. Health Psychol. 2012;31(1):114–21.
    1. Rivet Amico K, Bekker LG. Global PrEP roll‐out: recommendations for programmatic success. Lancet HIV. 2019;6(2):e137–40.
    1. UNAIDS . Getting on the Fast‐Track: The life‐cycle approach to HIV, Finding solutions for everyone at every stage of life [cited 2020 Apr 19]. Available from:
    1. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Antiretroviral therapy for the prevention of HIV‐1 transmission. N Engl J Med. 2016;375(9):830–9.
    1. Regulation of the Ministry of Public Health on Persons Assigned by the Ministry, Department, Bureau, Bangkok Metropolitan Administration, Pattaya City Administration, Provincial Administration Organization, Municipality or Local Administration Organization Published in the Government Gazette or by The Thai Red Cross Society to work as Pharmaceutical Professionals under Supervision of the Officials Who Perform a Pharmaceutical Profession. B.E. 2562 2019. [cited 2020 May 31]. Available from:
    1. Liu A, Stojanovski K, Lester R, Amico KR, McMahan V, Goicochea P, et al.Developing and implementing a mobile health (mHealth) adherence support system for HIV‐uninfected men who have sex with men (MSM) taking pre‐exposure prophylaxis (PrEP): the iText study. Abstract 165. 8th International Conference on HIV Treatment and Prevention Adherence; Miami, FL; 2014.
    1. WHO . Implementation Tool for Pre‐Exposure Prophylaxis of HIV Infection. Module 5: Monitoring and Evaluation. Geneva: World Health Organization; (WHO/CDS/HIV/18.10). 2018.
    1. Baker Z, Javanbakht M, Mierzwa S, Pavel C, Lally M, Zimet G, et al. Predictors of over‐reporting hiv pre‐exposure prophylaxis (PrEP) adherence among young men who have sex with men (YMSM) in self‐reported versus biomarker data. AIDS Behav. 2018;22(4):1174–83.
    1. Jacobson J, Siraprapasiri S. Estimation of PrEP targets for key and high‐risk populations in Thailand, 2020‐2022 [cited 2020 Apr 19]. Available from:
    1. AVAC Global Advocacy for HIV Prevention . Global PrEP tracker [cited 2020 Apr 19]. Available from: ;
    1. Aloysius I, Savage A, Zdravkov J, Korologou‐Linden R, Hill A, Smith R, et al. Internet‐based pre‐exposure prophylaxis with generic tenofovir DF/emtricitabine in London: an analysis of outcomes in 641 patients. J Virus Erad. 2017;3(4):218–22.
    1. Zablotska IB, Selvey C, Guy R, Price K, Holden J, Schmidt HM, et al. Expanded HIV pre‐exposure prophylaxis (PrEP) implementation in communities in New South Wales, Australia (EPIC‐NSW): design of an open label, single arm implementation trial. BMC Public Health. 2018;18(1):210.

Source: PubMed

3
Abonner